SYNBIOTIC SE |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.82 EUR | +13.95% |
|
-6.40% | +217.73% |
| Apr. 23 | SynBiotic Boosts CBD Business with Ilesol Pharmaceuticals Takeover | MT |
| Apr. 23 | SynBiotic SE acquired Ilesol Pharmaceuticals d.o.o. za proizvodnju i usluge. | CI |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 47.7 | 97.53 | 37.92 | 44.46 | 44.46 | - |
| Enterprise Value (EV) 1 | 47.7 | 97.69 | 40.69 | 44.96 | 47.56 | 45.76 |
| P/E ratio | -37.9 x | -7.04 x | -1.73 x | -22.6 x | -106 x | - |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 8.76 x | 10.8 x | 4.64 x | 3.09 x | 2.6 x | - |
| EV / Revenue | 8.76 x | 10.8 x | 4.98 x | 3.12 x | 2.78 x | - |
| EV / EBITDA | - | -20.2 x | -5.49 x | -37.5 x | 31.7 x | 12.7 x |
| EV / FCF | - | -17.7 x | -5.59 x | -10.7 x | -18.3 x | - |
| FCF Yield | - | -5.64% | -17.9% | -9.34% | -5.47% | - |
| Price to Book | - | 3.06 x | 1.86 x | 1.32 x | 1.34 x | - |
| Nbr of stocks (in thousands) | 2,250 | 3,340 | 3,674 | 4,680 | 4,680 | - |
| Reference price 2 | 21.20 | 29.20 | 10.32 | 9.500 | 9.500 | 9.500 |
| Announcement Date | 6/21/21 | 10/28/22 | 8/21/23 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net sales 1 | 5.446 | 9.06 | 8.166 | 14.4 | 17.1 | - |
| EBITDA 1 | - | -4.83 | -7.411 | -1.2 | 1.5 | 3.6 |
| EBIT 1 | - | -5.58 | -25.92 | -2.3 | -0.2 | - |
| Operating Margin | - | -61.59% | -317.47% | -15.97% | -1.17% | - |
| Earnings before Tax (EBT) 1 | - | -13.36 | -26.19 | -2.4 | -0.5 | - |
| Net income 1 | -0.8804 | -12.72 | -24.36 | -2 | -0.4 | - |
| Net margin | -16.17% | -140.4% | -298.35% | -13.89% | -2.34% | - |
| EPS 2 | -0.5600 | -4.150 | -5.970 | -0.4200 | -0.0900 | - |
| Free Cash Flow 1 | - | -5.51 | -7.274 | -4.2 | -2.6 | - |
| FCF margin | - | -60.82% | -89.08% | -29.17% | -15.2% | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 6/21/21 | 10/28/22 | 8/21/23 | - | - | - |
1EUR in Million2EUR
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | 0.16 | 2.77 | 0.5 | 3.1 | 1.3 |
| Net Cash position 1 | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | -0.0331 x | -0.3742 x | -0.4167 x | 2.067 x | 0.3611 x |
| Free Cash Flow 1 | - | -5.51 | -7.27 | -4.2 | -2.6 | - |
| ROE (net income / shareholders' equity) | - | -42% | -84.6% | -5.9% | -1.3% | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - |
| Book Value Per Share 2 | - | 9.530 | 5.540 | 7.200 | 7.110 | - |
| Cash Flow per Share 2 | - | -1.800 | -1.710 | -0.1300 | 0.1700 | - |
| Capex 1 | - | 0.37 | 0.28 | 4 | 4 | 4 |
| Capex / Sales | - | 4.08% | 3.41% | 27.78% | 23.39% | - |
| Announcement Date | 6/21/21 | 10/28/22 | 8/21/23 | - | - | - |
1EUR in Million2EUR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
9.5
EUR
Average target price
15.2
EUR
Spread / Average Target
+60.00%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +217.73% | 47.64M | |
| +25.05% | 3.73B | |
| +112.12% | 2.03B | |
| +80.95% | 59.76M |
- Stock Market
- Equities
- SBX Stock
- Financials SynBiotic SE
